vs
Side-by-side financial comparison of Dine Brands Global, Inc. (DIN) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $217.6M, roughly 1.3× Dine Brands Global, Inc.). Dine Brands Global, Inc. runs the higher net margin — -5.6% vs -45.7%, a 40.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 6.3%). Dine Brands Global, Inc. produced more free cash flow last quarter ($-8.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.7%).
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
DIN vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $217.6M | $281.3M |
| Net Profit | $-12.2M | $-128.5M |
| Gross Margin | 42.4% | 64.6% |
| Operating Margin | -7.6% | -43.0% |
| Net Margin | -5.6% | -45.7% |
| Revenue YoY | 6.3% | 39.4% |
| Net Profit YoY | -336.1% | -15.8% |
| EPS (diluted) | $-0.79 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $217.6M | $281.3M | ||
| Q3 25 | $216.2M | $265.2M | ||
| Q2 25 | $230.8M | $232.1M | ||
| Q1 25 | $214.8M | $203.5M | ||
| Q4 24 | $204.8M | $201.8M | ||
| Q3 24 | $195.0M | $191.5M | ||
| Q2 24 | $206.3M | $177.2M | ||
| Q1 24 | $206.2M | $168.5M |
| Q4 25 | $-12.2M | $-128.5M | ||
| Q3 25 | $7.3M | $-92.7M | ||
| Q2 25 | $13.8M | $-99.9M | ||
| Q1 25 | $8.2M | $-95.2M | ||
| Q4 24 | $5.2M | $-111.0M | ||
| Q3 24 | $19.1M | $-107.8M | ||
| Q2 24 | $23.2M | $-102.6M | ||
| Q1 24 | $17.5M | $-115.0M |
| Q4 25 | 42.4% | 64.6% | ||
| Q3 25 | 39.1% | 64.7% | ||
| Q2 25 | 40.0% | 65.0% | ||
| Q1 25 | 42.0% | 63.3% | ||
| Q4 24 | 41.7% | 61.6% | ||
| Q3 24 | 47.8% | 61.1% | ||
| Q2 24 | 48.1% | 59.1% | ||
| Q1 24 | 47.2% | 61.2% |
| Q4 25 | -7.6% | -43.0% | ||
| Q3 25 | 4.7% | -37.3% | ||
| Q2 25 | 8.2% | -45.9% | ||
| Q1 25 | 6.0% | -54.6% | ||
| Q4 24 | 3.8% | -62.4% | ||
| Q3 24 | 13.6% | -61.3% | ||
| Q2 24 | 15.1% | -56.8% | ||
| Q1 24 | 11.7% | -59.2% |
| Q4 25 | -5.6% | -45.7% | ||
| Q3 25 | 3.4% | -35.0% | ||
| Q2 25 | 6.0% | -43.0% | ||
| Q1 25 | 3.8% | -46.8% | ||
| Q4 24 | 2.5% | -55.0% | ||
| Q3 24 | 9.8% | -56.3% | ||
| Q2 24 | 11.2% | -57.9% | ||
| Q1 24 | 8.5% | -68.2% |
| Q4 25 | $-0.79 | $-1.01 | ||
| Q3 25 | $0.48 | $-0.74 | ||
| Q2 25 | $0.89 | $-0.80 | ||
| Q1 25 | $0.53 | $-0.77 | ||
| Q4 24 | $0.35 | $-0.90 | ||
| Q3 24 | $1.24 | $-0.88 | ||
| Q2 24 | $1.50 | $-0.84 | ||
| Q1 24 | $1.13 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.2M | $378.2M |
| Total DebtLower is stronger | $1.2B | $1.5B |
| Stockholders' EquityBook value | $-273.9M | $-99.3M |
| Total Assets | $1.7B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.2M | $378.2M | ||
| Q3 25 | $167.9M | $580.0M | ||
| Q2 25 | $194.2M | $629.1M | ||
| Q1 25 | $186.5M | $698.6M | ||
| Q4 24 | $186.7M | $525.5M | ||
| Q3 24 | $169.6M | $585.0M | ||
| Q2 24 | $153.5M | $933.7M | ||
| Q1 24 | $145.0M | $1.0B |
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $-273.9M | $-99.3M | ||
| Q3 25 | $-231.9M | $-354.5M | ||
| Q2 25 | $-212.5M | $-305.5M | ||
| Q1 25 | $-215.7M | $-250.8M | ||
| Q4 24 | $-216.0M | $-139.6M | ||
| Q3 24 | $-216.7M | $-60.1M | ||
| Q2 24 | $-231.7M | $-1.6M | ||
| Q1 24 | $-244.8M | $68.3M |
| Q4 25 | $1.7B | $2.0B | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.6B | ||
| Q1 24 | $1.7B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.7M | $-26.4M |
| Free Cash FlowOCF − Capex | $-8.6M | $-54.2M |
| FCF MarginFCF / Revenue | -3.9% | -19.3% |
| Capex IntensityCapex / Revenue | 6.6% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $53.4M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.7M | $-26.4M | ||
| Q3 25 | $30.2M | $-35.4M | ||
| Q2 25 | $37.0M | $-60.3M | ||
| Q1 25 | $16.1M | $-62.7M | ||
| Q4 24 | $30.5M | $-64.5M | ||
| Q3 24 | $25.5M | $-51.1M | ||
| Q2 24 | $21.6M | $-94.0M | ||
| Q1 24 | $30.6M | $-30.3M |
| Q4 25 | $-8.6M | $-54.2M | ||
| Q3 25 | $18.1M | $-45.8M | ||
| Q2 25 | $31.0M | $-65.9M | ||
| Q1 25 | $12.8M | $-67.1M | ||
| Q4 24 | $26.7M | $-83.4M | ||
| Q3 24 | $22.0M | $-55.3M | ||
| Q2 24 | $18.2M | $-99.1M | ||
| Q1 24 | $27.2M | $-37.2M |
| Q4 25 | -3.9% | -19.3% | ||
| Q3 25 | 8.4% | -17.3% | ||
| Q2 25 | 13.4% | -28.4% | ||
| Q1 25 | 6.0% | -33.0% | ||
| Q4 24 | 13.0% | -41.3% | ||
| Q3 24 | 11.3% | -28.9% | ||
| Q2 24 | 8.8% | -55.9% | ||
| Q1 24 | 13.2% | -22.1% |
| Q4 25 | 6.6% | 9.9% | ||
| Q3 25 | 5.6% | 3.9% | ||
| Q2 25 | 2.6% | 2.4% | ||
| Q1 25 | 1.5% | 2.2% | ||
| Q4 24 | 1.9% | 9.4% | ||
| Q3 24 | 1.8% | 2.2% | ||
| Q2 24 | 1.7% | 2.9% | ||
| Q1 24 | 1.6% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 4.12× | — | ||
| Q2 25 | 2.68× | — | ||
| Q1 25 | 1.97× | — | ||
| Q4 24 | 5.88× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 1.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
